{"id":"W4388589580","doi":"10.1093/neuonc/noad179.0366","title":"CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Regorafenib; Medicine; Clinical endpoint; Randomization; Randomized controlled trial; Internal medicine; Oncology; Hazard ratio; Confidence interval; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007129747,0.0002441512,0.00134555,0.000426683,0.0002322956,0.00003919911,0.0002920838,0.0003032582,0.0001281874],"category_scores_gemma":[0.007324341,0.0003070245,0.0001823452,0.0002612442,0.0001792487,0.0002803,0.0001362463,0.0002152541,0.0003650433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000498315,"about_ca_system_score_gemma":0.0002205717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003314913,"about_ca_topic_score_gemma":0.0004079865,"domain_scores_codex":[0.9944227,0.0002127015,0.003907644,0.0008078754,0.0000996629,0.0005494558],"domain_scores_gemma":[0.9911657,0.005711613,0.00233141,0.000495485,0.00006525478,0.0002305684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02470815,0.00203485,0.002734459,0.0009575027,0.0002143617,0.00003778322,0.0159288,0.0003402282,0.0007314987,0.04364468,0.9023474,0.006320276],"study_design_scores_gemma":[0.07382165,0.005363597,0.001010854,0.00005363046,0.00001667161,0.0000124207,0.002162769,0.006070523,0.0005379739,0.004498242,0.9060258,0.000425909],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9505019,0.001019916,0.0001011453,0.03397772,0.005245151,0.003456838,0.001396739,0.0001329464,0.004167631],"genre_scores_gemma":[0.9893951,0.0009004358,0.00132046,0.004397563,0.001676036,0.0014737,0.0003436937,0.00009635,0.0003966604],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0491135,"threshold_uncertainty_score":0.9999382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3845344680919263,"score_gpt":0.455586521230215,"score_spread":0.07105205313828872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}